Looks a sound strategy by the board. As a holder of IPG and ECL, I rate the I CMI business highly with good growth prospects, and can see greater value in the hands of IPG management. However the CMI business is cyclical in nature, so it won't offer up any more stability in earnings.
The numbers stack up for IPG. The current guidance today is for 1H24 EBIT for IPD Group to be up about 20%. If we assume FY24 EBIT of about $27m (standalone basis) and an EV of about $340m, IPG is trading at over 12x FY24 EBIT, well above the offer price of about 7x CMI FY24 EBIT. So the arbitrage works.
Proposed debt looks modest, although bear in mind it could creep higher due to the high working capital requirements of these businesses.
- Forums
- ASX - By Stock
- Ann: Trading Halt
Looks a sound strategy by the board. As a holder of IPG and ECL,...
Featured News
Add IPG (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.74 |
Change
0.000(0.00%) |
Mkt cap ! $491.5M |
Open | High | Low | Value | Volume |
$4.74 | $4.77 | $4.66 | $195.3K | 41.35K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1122 | $4.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.80 | 4250 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1122 | 4.700 |
2 | 934 | 4.680 |
2 | 2200 | 4.650 |
1 | 1082 | 4.620 |
5 | 7750 | 4.600 |
Price($) | Vol. | No. |
---|---|---|
4.800 | 4250 | 2 |
4.840 | 425 | 1 |
4.850 | 5647 | 2 |
4.900 | 3287 | 3 |
4.930 | 5000 | 1 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
IPG (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online